Canaccord Genuity Maintains Buy on Helus Pharma, Raises Price Target to $58

Benzinga · 1d ago
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $42 to $58.